Hot on the heels, Aurinia launches its drug in the Lupus market after GSK
Aurinia Pharmaceuticals has recently got the USFDA approval for its Lupkynis (voclosporin) in combination with a background immunosuppressive therapy regimen to treat adult patients with active Lupus nephritis (LN). Lupkynis is the first oral therapy to receive FDA nod for Lupus nephritis, a condition that causes inflammation of kidneys. It is one of the most common and serious complications of the autoimmune disease systemic lupus erythematosus (SLE).
Lupus has been a challenging condition to treat for decades with only a limited number of therapeutic options. However, Aurinia is no...
